{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:23:55Z","timestamp":1785871435389,"version":"3.56.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["521659142"],"award-info":[{"award-number":["521659142"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1074, B6"],"award-info":[{"award-number":["SFB1074, B6"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1074, B6"],"award-info":[{"award-number":["SFB1074, B6"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2023.01"],"award-info":[{"award-number":["DKS 2023.01"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of T-cell precursors. Although the survival rates have improved with the use of intensive chemotherapy, the emergence of relapse as well as treatment-related morbidity and mortality remain major challenges. Novel treatment approaches include the inhibition of anti-apoptotic regulators or cellular immunotherapies. Here, we analyzed the sensitivity of T-ALL to inhibitors of BCL-2 (venetoclax), BCL-XL (A1331852), MCL-1 (AZD5991) and dual inhibition of BCL-2\/BCL-XL (AZD4320) and evaluated their combination effects with natural killer (NK) cells. While only early T-cell precursor (ETP) ALL was sensitive to BCL-2 inhibition, MCL-1 inhibition alone was not effective in most cell lines and patient-derived xenograft (PDX) samples. For BCL-XL and dual BCL-2\/BCL-XL inhibition, we observed heterogeneous sensitivities, which were associated with anti-apoptotic dependencies on the respective BCL-2 family members as assessed by BH3-profiling. Moreover, we identified functional shifts in anti-apoptotic dependencies upon exposure to AZD4320 or AZD5991 alone and synergistic effects when both inhibitors were combined with each other, allowing cell death induction in resistant samples. We then explored the potential use of apoptosis-inducing drugs as sensitizers for immunotherapy. Therefore, we investigated the potential of NK cell-mediated killing in T-ALL and found heterogeneous sensitivity, with some cell lines showing responses even at low effector-to-target (E:T) ratios. Importantly, NK cell-mediated killing could be further enhanced by combining NK cells with AZD4320, proposing this combination as a potential effective treatment. Taken together, we demonstrated promising potential of BH3-mimetics and NK cells for the treatment of T-ALL alone and in combination, warranting further preclinical and potential clinical evaluation.<\/jats:p>","DOI":"10.1038\/s41419-026-08698-x","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:07:06Z","timestamp":1775279226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic potential of BH3-mimetics and NK cell-mediated immunotherapy in T-ALL"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9979-9109","authenticated-orcid":false,"given":"Colin","family":"Fortner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Niedermayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7998-6010","authenticated-orcid":false,"given":"Melina Maria","family":"B\u00e4uerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren Christiane","family":"Wichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J\u00f6rg","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Michael","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2650-586X","authenticated-orcid":false,"given":"Meike","family":"Vogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-7544","authenticated-orcid":false,"given":"L\u00fcder Hinrich","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-3001","authenticated-orcid":false,"given":"Felix","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"8698_CR1","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1172\/JCI61269","volume":"122","author":"P Van Vlierberghe","year":"2012","unstructured":"Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012;122:3398\u2013406.","journal-title":"J Clin Invest"},{"key":"8698_CR2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/sj.leu.2404302","volume":"20","author":"C Graux","year":"2006","unstructured":"Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496\u2013510.","journal-title":"Leukemia"},{"key":"8698_CR3","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016:580\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"8698_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.","journal-title":"Blood Cancer J"},{"key":"8698_CR5","doi-asserted-by":"crossref","unstructured":"Buckley M, Yeung DT, White DL, Eadie LN. T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments. Leukemia. 2025;39:1294\u2013310.","DOI":"10.1038\/s41375-025-02599-2"},{"key":"8698_CR6","doi-asserted-by":"crossref","unstructured":"Genesc\u00e0 E, la Starza R. Early T-cell precursor ALL and beyond: immature and ambiguous lineage T-ALL subsets. Cancers. 2022;14:1873.","DOI":"10.3390\/cancers14081873"},{"key":"8698_CR7","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41375-024-02264-0","volume":"38","author":"M Neumann","year":"2024","unstructured":"Neumann M, Beder T, Bastian L, H\u00e4nzelmann S, Bultmann M, Wolgast N, et al. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols. Leukemia. 2024;38:1213\u201322.","journal-title":"Leukemia"},{"key":"8698_CR8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet. 2017;49:1211\u20138.","journal-title":"Nat Genet"},{"key":"8698_CR9","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","volume":"127","author":"N Jain","year":"2016","unstructured":"Jain N, Lamb AV, O\u2019Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863\u20139.","journal-title":"Blood"},{"key":"8698_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147\u201356.","journal-title":"Lancet Oncol"},{"key":"8698_CR11","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S2352-3026(15)00254-9","volume":"3","author":"V Conter","year":"2016","unstructured":"Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, et al. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 2016;3:e80\u20136.","journal-title":"Lancet Haematol"},{"key":"8698_CR12","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","volume":"99","author":"D Hoelzer","year":"2002","unstructured":"Hoelzer D, G\u00f6kbuget N, Digel W, Faak T, Kneba M, Reutzel R, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002;99:4379\u201385.","journal-title":"Blood"},{"key":"8698_CR13","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","volume":"20","author":"DT Teachey","year":"2019","unstructured":"Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019;20:e142\u2013e54.","journal-title":"Lancet Oncol"},{"key":"8698_CR14","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41375-022-01558-5","volume":"36","author":"K Bodaar","year":"2022","unstructured":"Bodaar K, Yamagata N, Barthe A, Landrigan J, Chonghaile TN, Burns M, et al. JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2022;36:1499\u2013507.","journal-title":"Leukemia"},{"key":"8698_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1182\/blood.V87.3.1140.bloodjournal8731140","volume":"87","author":"E Coustan-Smith","year":"1996","unstructured":"Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 1996;87:1140\u20136.","journal-title":"Blood"},{"key":"8698_CR16","doi-asserted-by":"crossref","unstructured":"Tait SW, Green DR. Mitochondrial regulation of cell death. Cold Spring Harb Perspect Biol. 2013;5:a008706.","DOI":"10.1101\/cshperspect.a008706"},{"key":"8698_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8698_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"8698_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375\u201388.","journal-title":"Cancer Cell"},{"key":"8698_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Venetoclax: first global approval. Drugs. 2016;76:979\u201387.","journal-title":"Drugs"},{"key":"8698_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"8698_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768\u201378.","journal-title":"Lancet Oncol"},{"key":"8698_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"8698_CR24","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074\u201387.","journal-title":"Cancer Discov"},{"key":"8698_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.","journal-title":"Cell Death Dis"},{"key":"8698_CR26","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","volume":"75","author":"SE Alford","year":"2015","unstructured":"Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75:1366\u201375.","journal-title":"Cancer Res"},{"key":"8698_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101015","volume":"23","author":"ML Rasmussen","year":"2020","unstructured":"Rasmussen ML, Taneja N, Neininger AC, Wang L, Robertson GL, Riffle SN, et al. MCL-1 inhibition by selective bh3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. iScience. 2020;23:101015.","journal-title":"iScience"},{"key":"8698_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","volume":"3","author":"J Yuda","year":"2023","unstructured":"Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023;3:154.","journal-title":"Commun Med (Lond)"},{"key":"8698_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","volume":"13","author":"A Bolomsky","year":"2020","unstructured":"Bolomsky A, Vogler M, Kose MC, Heckman CA, Ehx G, Ludwig H, et al. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol. 2020;13:173.","journal-title":"J Hematol Oncol"},{"key":"8698_CR30","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1021\/acsmedchemlett.9b00568","volume":"11","author":"L Wang","year":"2020","unstructured":"Wang L, Doherty GA, Judd AS, Tao ZF, Hansen TM, Frey RR, et al. Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-X(L) inhibitor. ACS Med Chem Lett. 2020;11:1829\u201336.","journal-title":"ACS Med Chem Lett"},{"key":"8698_CR31","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118:1663\u201374.","journal-title":"Blood"},{"key":"8698_CR32","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149\u201359.","journal-title":"Lancet Oncol"},{"key":"8698_CR33","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","volume":"56","author":"TJ Kipps","year":"2015","unstructured":"Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:2826\u201333.","journal-title":"Leuk Lymphoma"},{"key":"8698_CR34","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","volume":"26","author":"SB Balachander","year":"2020","unstructured":"Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, Lewis P, et al. AZD4320, A dual inhibitor of Bcl-2 and Bcl-x(L), induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia. Clin Cancer Res. 2020;26:6535\u201349.","journal-title":"Clin Cancer Res"},{"key":"8698_CR35","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s00277-023-05286-3","volume":"102","author":"YH Huang","year":"2023","unstructured":"Huang YH, Wan CL, Dai HP, Xue SL. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia\/lymphoma. Ann Hematol. 2023;102:2001\u201313.","journal-title":"Ann Hematol"},{"key":"8698_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40164-022-00368-w","volume":"12","author":"D Caracciolo","year":"2023","unstructured":"Caracciolo D, Mancuso A, Poler\u00e0 N, Froio C, D\u2019Aquino G, Riillo C, et al. The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives. Exp Hematol Oncol. 2023;12:5.","journal-title":"Exp Hematol Oncol"},{"key":"8698_CR37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557\u201375.","journal-title":"Nat Rev Cancer"},{"key":"8698_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30:772\u201384.","journal-title":"Nat Med"},{"key":"8698_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1777651","volume":"9","author":"LM Reindl","year":"2020","unstructured":"Reindl LM, Albinger N, Bexte T, M\u00fcller S, Hartmann J, Ullrich E. Immunotherapy with NK cells: recent developments in gene modification open up new avenues. Oncoimmunology. 2020;9:1777651.","journal-title":"Oncoimmunology"},{"key":"8698_CR40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21:315\u201331.","journal-title":"Cell Mol Immunol"},{"key":"8698_CR41","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","volume":"185","author":"R Pan","year":"2022","unstructured":"Pan R, Ryan J, Pan D, Wucherpfennig KW, Letai A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022;185:1521\u201338.e18.","journal-title":"Cell"},{"key":"8698_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41420-021-00812-6","volume":"8","author":"V Sarchen","year":"2022","unstructured":"Sarchen V, Shanmugalingam S, Kehr S, Reindl LM, Greze V, Wiedemann S, et al. Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy. Cell Death Discov. 2022;8:11.","journal-title":"Cell Death Discov"},{"key":"8698_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ccr.2010.11.014","volume":"19","author":"LH Meyer","year":"2011","unstructured":"Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, Stursberg J, et al. Early relapse in ALL is identified by time to leukemia in NOD\/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell. 2011;19:206\u201317.","journal-title":"Cancer Cell"},{"key":"8698_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharm Res Perspect. 2015;3:e00149.","journal-title":"Pharm Res Perspect"},{"key":"8698_CR45","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/1087057114521867","volume":"19","author":"W Zhao","year":"2014","unstructured":"Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H. A new bliss independence model to analyze drug combination data. J Biomol Screen. 2014;19:817\u201321.","journal-title":"J Biomol Screen"},{"key":"8698_CR46","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u2013w43.","journal-title":"Nucleic Acids Res"},{"key":"8698_CR47","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1182\/bloodadvances.2022007728","volume":"7","author":"EA Olesinski","year":"2023","unstructured":"Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, et al. BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia. Blood Adv. 2023;7:2917\u201323.","journal-title":"Blood Adv"},{"key":"8698_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/B978-0-12-385493-3.00004-8","volume":"103","author":"D Wlodkowic","year":"2011","unstructured":"Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z. Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol. 2011;103:55\u201398.","journal-title":"Methods Cell Biol"},{"key":"8698_CR49","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Lepp\u00e4 AM, Renders S, Stumpf K, Reyneri C, Betz B, et al. Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax. Cancer Discov. 2023;13:1408\u201327.","journal-title":"Cancer Discov"},{"key":"8698_CR50","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","volume":"105","author":"I Prager","year":"2019","unstructured":"Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105:1319\u201329.","journal-title":"J Leukoc Biol"},{"key":"8698_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503\u201310.","journal-title":"Nat Immunol"},{"key":"8698_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05534-8","volume":"22","author":"M Mohammad Taheri","year":"2024","unstructured":"Mohammad Taheri M, Javan F, Poudineh M, Athari SS. Beyond CAR-T: the rise of CAR-NK cell therapy in asthma immunotherapy. J Transl Med. 2024;22:736.","journal-title":"J Transl Med"},{"key":"8698_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","volume":"32","author":"VA Guerra","year":"2019","unstructured":"Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pr Res Clin Haematol. 2019;32:145\u201353.","journal-title":"Best Pr Res Clin Haematol"},{"key":"8698_CR54","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/bloodadvances.2023012231","volume":"8","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, et al. A phase 1\/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Adv. 2024;8:909\u201315.","journal-title":"Blood Adv"},{"key":"8698_CR55","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11:1440\u201353.","journal-title":"Cancer Discov"},{"key":"8698_CR56","doi-asserted-by":"crossref","unstructured":"Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, et al. Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers. 2021;14:150.","DOI":"10.3390\/cancers14010150"},{"key":"8698_CR57","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, Ross DM, Powell JA, Pitson SM. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis. 2024;15:413.","journal-title":"Cell Death Dis"},{"key":"8698_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06864-7","volume":"15","author":"S Enzenmuller","year":"2024","unstructured":"Enzenmuller S, Niedermayer A, Seyfried F, Muench V, Tews D, Rupp U, et al. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation. Cell Death Dis. 2024;15:475.","journal-title":"Cell Death Dis"},{"key":"8698_CR59","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","volume":"104","author":"E Tausch","year":"2019","unstructured":"Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104:e434\u2013e7.","journal-title":"Haematologica"},{"key":"8698_CR60","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1158\/2159-8290.CD-21-1334","volume":"12","author":"J Montero","year":"2022","unstructured":"Montero J, Haq R. Adapted to survive: targeting cancer cells with BH3 mimetics. Cancer Discov. 2022;12:1217\u201332.","journal-title":"Cancer Discov"},{"key":"8698_CR61","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.1182\/bloodadvances.2024013194","volume":"8","author":"MC Wichert","year":"2024","unstructured":"Wichert MC, Fortner C, Niedermayer A, Bender J, Enzenmuller S, Debatin KM, et al. The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL. Blood Adv. 2024;8:6035\u201342.","journal-title":"Blood Adv"},{"key":"8698_CR62","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1182\/bloodadvances.2024012906","volume":"8","author":"A Dolnikova","year":"2024","unstructured":"Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen CD, et al. Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status. Blood Adv. 2024;8:3532\u201343.","journal-title":"Blood Adv"},{"key":"8698_CR63","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41375-021-01502-z","volume":"36","author":"F Seyfried","year":"2022","unstructured":"Seyfried F, Stirnweiss FU, Niedermayer A, Enzenmuller S, Horl RL, Munch V, et al. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL. Leukemia. 2022;36:901\u201312.","journal-title":"Leukemia"},{"key":"8698_CR64","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1083\/jcb.201706134","volume":"216","author":"G Sun","year":"2017","unstructured":"Sun G, Guzman E, Balasanyan V, Conner CM, Wong K, Zhou HR, et al. A molecular signature for anastasis, recovery from the brink of apoptotic cell death. J Cell Biol. 2017;216:3355\u201368.","journal-title":"J Cell Biol"},{"key":"8698_CR65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2216531120","volume":"120","author":"M Nano","year":"2023","unstructured":"Nano M, Mondo JA, Harwood J, Balasanyan V, Montell DJ. Cell survival following direct executioner-caspase activation. Proc Natl Acad Sci USA. 2023;120:e2216531120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8698_CR66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.semcdb.2023.07.005","volume":"156","author":"G Sun","year":"2024","unstructured":"Sun G. Death and survival from executioner caspase activation. Semin Cell Dev. Biol. 2024;156:66\u201373.","journal-title":"Semin Cell Dev. Biol"},{"key":"8698_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1801-0","volume":"10","author":"F Seyfried","year":"2019","unstructured":"Seyfried F, Demir S, Horl RL, Stirnweiss FU, Ryan J, Scheffold A, et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 2019;10:571.","journal-title":"Cell Death Dis"},{"key":"8698_CR68","doi-asserted-by":"crossref","unstructured":"Niedermayer A, Stursberg J, Bergmann AK, Zimmermann M, Cario G, Bruggemann M, et al. Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax. Leukemia. 2025;39:1520\u20135.","DOI":"10.1038\/s41375-025-02591-w"},{"key":"8698_CR69","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41416-020-0795-9","volume":"122","author":"A Bierbrauer","year":"2020","unstructured":"Bierbrauer A, Jacob M, Vogler M, Fulda S. A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. Br J Cancer. 2020;122:1544\u201351.","journal-title":"Br J Cancer"},{"key":"8698_CR70","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1515\/hsz-2016-0107","volume":"397","author":"J Ryan","year":"2016","unstructured":"Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397:671\u20138.","journal-title":"Biol Chem"},{"key":"8698_CR71","doi-asserted-by":"crossref","unstructured":"Gong JN, Djajawi TM, Moujalled DM, Pomilio G, Khong T, Zhang LP, et al. Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins. Cell Death Differ. 2025;32:1382\u201396.","DOI":"10.1038\/s41418-025-01487-7"},{"key":"8698_CR72","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022;140:2113\u201326.","journal-title":"Blood"},{"key":"8698_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38552-z","volume":"14","author":"DS Potter","year":"2023","unstructured":"Potter DS, Du R, Bohl SR, Chow KH, Ligon KL, Bueno R, et al. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma. Nat Commun. 2023;14:2897.","journal-title":"Nat Commun"},{"key":"8698_CR74","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","volume":"12","author":"J Deng","year":"2007","unstructured":"Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12:171\u201385.","journal-title":"Cancer Cell"},{"key":"8698_CR75","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","volume":"10","author":"M Vogler","year":"2025","unstructured":"Vogler M, Braun Y, Smith VM, Westhoff M-A, Pereira RS, Pieper NM, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. 2025;10:91.","journal-title":"Signal Transduct Target Ther"},{"key":"8698_CR76","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3324\/haematol.2022.280631","volume":"108","author":"MA Fischer","year":"2023","unstructured":"Fischer MA, Song Y, Arrate MP, Gbyli R, Villaume MT, Smith BN, et al. Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes. Haematologica. 2023;108:522\u201331.","journal-title":"Haematologica"},{"key":"8698_CR77","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","volume":"4","author":"CM Patterson","year":"2021","unstructured":"Patterson CM, Balachander SB, Grant I, Pop-Damkov P, Kelly B, McCoull W, et al. Design and optimisation of dendrimer-conjugated Bcl-2\/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021;4:112.","journal-title":"Commun Biol"},{"key":"8698_CR78","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1158\/0008-5472.CAN-11-1732","volume":"71","author":"LH Meyer","year":"2011","unstructured":"Meyer LH, Debatin KM. Diversity of human leukemia xenograft mouse models: implications for disease biology. Cancer Res. 2011;71:7141\u20134.","journal-title":"Cancer Res"},{"key":"8698_CR79","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73:5315\u20139.","journal-title":"Cancer Res"},{"key":"8698_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09186-x","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng F, Kov\u00e1cs IA, Barab\u00e1si A-L. Network-based prediction of drug combinations. Nat Commun. 2019;10:1197.","journal-title":"Nat Commun"},{"key":"8698_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte D, Vale N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr Res Pharmacol Drug Discov. 2022;3:100110.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"8698_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/srep07160","volume":"4","author":"H Huang","year":"2014","unstructured":"Huang H, Zhang P, Qu XA, Sanseau P, Yang L. Systematic prediction of drug combinations based on clinical side-effects. Sci Rep. 2014;4:7160.","journal-title":"Sci Rep"},{"key":"8698_CR83","first-page":"64","volume":"9","author":"F You","year":"2019","unstructured":"You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L, et al. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9:64\u201378.","journal-title":"Am J Cancer Res"},{"key":"8698_CR84","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","volume":"56","author":"O Dufva","year":"2023","unstructured":"Dufva O, Gandolfi S, Huuhtanen J, Dashevsky O, Duan H, Saeed K, et al. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity. 2023;56:2816\u201335 e13.","journal-title":"Immunity"},{"key":"8698_CR85","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141:856\u201368.","journal-title":"Blood"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08698-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:02:16Z","timestamp":1775818936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08698-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8698"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08698-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was carried out in accordance with the Declaration of Helsinki. Human samples were obtained after written informed consent from the participants or their legal guardians. The study was approved by the Ethics Committee of Ulm University (approval number 461\/19).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"387"}}